Method for quantifying cognitive dysfunction disease biomarker using mass spectrometry and mass spectrometer

Abstract

The invention discloses a method for quantifying a cognitive dysfunction disease biomarker using mass spectrometry and a mass spectrometer. The provided method is capable of specifically and sensitively detect a cognitive dysfunction disease biomarker in a biological sample in a short time. In the present invention, multiple reaction monitoring (MRM) measurements of at least one peptide selected from the group consisting of 14 peptides as biomarkers of cognitive dysfunction diseases contained in a biological sample are performed using a mass spectrometer capable of MS / MS measurement, and the peptide is quantified based on a result thereof. In this case, for each peptide, an MRM transition which is a combination of a mass-to-charge ratio of a precursor ion and a mass-to-charge ratio of a product ion is stored in advance in a storage unit of the mass spectrometer as a measurement condition of the MRM measurement, and the MRM transition is used when cognitive dysfunction disease biomarkers are detected.

Description

technical field [0001] The present invention relates to a method and a mass spectrometry device for detecting and quantifying biomarkers of cognitive impairment diseases by quantifying various peptides using mass spectrometry. Background technique [0002] Cognitive dysfunction diseases such as Alzheimer's disease are diseases that cause a decrease in the memory ability and cognitive ability of patients, and the disease progresses gradually and continuously over 10 to 20 years. In severe cognitive dysfunction diseases that are exacerbated, not only the loss of memory function and cognitive function but also the breakdown of personality will occur, and the patients will lose their social life functions. Therefore, the development of effective therapeutic drugs is desired. [0003] Donepezil hydrochloride (donepezil) as an acetylcholinesterase inhibitor approved in Japan in 1999 as a therapeutic drug for Alzheimer-type dementia, and some therapeutic drugs have been developed a...

AI Technical Summary

Problems solved by technology

[0011] The method of (1) is usually used for the purpose of screening for cognitive impairment diseases, and cannot achieve a definitive diagnosis

In addition, HSD-R and MMSE cannot diagnose patients classified as severe cognitive impairment diseases (Non-Patent Document 1)

The method of (2) requires the use of special and expensive equipment, which is difficult to implement in all medical institutions

Furthermore, the methods (1) and (2) both cause differences in diagnostic results depending on the physician in charge, and thus lack objectivity.

[0012] Although the method of (3) has high diagnostic sensitivity and can carry out objective diagnosis, it is technically difficult to collect cerebrospinal fluid, and the current situation is that it has not been widely used.

Images